{"id":7333,"date":"2026-09-24T10:08:22","date_gmt":"2026-09-24T08:08:22","guid":{"rendered":"https:\/\/alpha1-deutschland.org\/?p=7333"},"modified":"2026-09-24T10:08:22","modified_gmt":"2026-09-24T08:08:22","slug":"alpha1-deutschland-unterwegs-in-europa","status":"publish","type":"post","link":"https:\/\/alpha1-deutschland.org\/en\/alpha1-deutschland-unterwegs-in-europa","title":{"rendered":"Alpha1 Germany traveling in Europe"},"content":{"rendered":"
<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t
<\/span><\/span>

Author<\/h4><\/span><\/span>\n<\/div>\n
\n\t

Marion Wilkens, as appeared in Alpha1 Journal 1\/2026<\/a>.<\/strong><\/p>\n<\/div>\n\n\n\n

<\/div><\/div>\n
\n\t

ERN-Lung, ELF, ERS, and EARCO \u2013 four organizations, four abbreviations, and one common "E." It stands for Europe. But for us, Europe is far more than a geographical term. It stands for Experience, United, Research, Opportunity, Patients, and Action. These six terms aptly describe why Alpha1 Germany is increasingly active at the European level.<\/p>\n

Rare diseases don't stop at national borders. Especially with a rare disease like alpha-1 antitrypsin deficiency, it's crucial to pool experiences, knowledge, and data across borders. Only together can we better understand the disease, advance research, and improve care. That's why it's a matter of course for us to contribute our voice wherever research, care, and the future of patient participation are discussed at the European level.<\/p>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t

<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t
<\/div><\/div>

Rare diseases don't stop at national borders. Especially with a rare disease like alpha-1 antitrypsin deficiency, it's important to pool experience, knowledge, and data across borders.<\/p>

<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n\t
\n\t\t